Compare GPCR & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GPCR | MFIC |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2023 | 2004 |
| Metric | GPCR | MFIC |
|---|---|---|
| Price | $68.72 | $11.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 6 |
| Target Price | ★ $97.90 | $12.63 |
| AVG Volume (30 Days) | ★ 1.2M | 833.1K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $324,678,000.00 |
| Revenue This Year | N/A | $9.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.73 |
| Revenue Growth | N/A | ★ 11.35 |
| 52 Week Low | $13.22 | $10.18 |
| 52 Week High | $94.90 | $14.74 |
| Indicator | GPCR | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 46.38 |
| Support Level | $61.99 | $11.04 |
| Resistance Level | $70.40 | $11.76 |
| Average True Range (ATR) | 4.03 | 0.23 |
| MACD | -1.08 | 0.00 |
| Stochastic Oscillator | 76.21 | 61.11 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.